{"title":"Histopathologic and Prognostic Significance of Tumor Budding in Colorectal Adenocarcinoma: A Retrospective Cohort Study Conducted in Shiraz, Iran.","authors":"Mohammad Hossein Anbardar, Nadia Rahimizadeh","doi":"10.30699/IJP.2023.1999329.3090","DOIUrl":null,"url":null,"abstract":"<p><strong>Background & objective: </strong>Colorectal cancer is the second reason for cancer-associated death. The prognosis of the malignancy is defined by TNM scoring. However, tumor grading, lymphovascular invasion, perineural invasion, and tumor buddings may affect its prognosis. This study aimed to assess the prognostic and histologic impact of tumor budding in colorectal adenocarcinoma.</p><p><strong>Methods: </strong>This study is a retrospective cohort of 192 patients with colorectal adenocarcinoma. All four stages of colorectal adenocarcinoma patients were included, but the patients in stages I and II were also analyzed separately. We used pathology reports to extract the histopathologic data. The prognostic values were extracted by calling the patients.</p><p><strong>Results: </strong>Less than half of the patients were in stages I and II of the disease. According to our analysis, tumor extension and lymphovascular invasion were correlated with tumor budding count in patients in stages I and II, and lymphovascular invasion, tumor grade, tumor stage, lymph node involvement, tumor extension, tumor site, metastasis, and five-year survival were correlated with tumor budding within all stages.</p><p><strong>Conclusion: </strong>It is recommended that tumor budding count should be assessed and reported in pathology reports of adenocarcinomas due to its high correlation with poor prognosis.</p>","PeriodicalId":38900,"journal":{"name":"Iranian Journal of Pathology","volume":"19 1","pages":"59-66"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11164312/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30699/IJP.2023.1999329.3090","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background & objective: Colorectal cancer is the second reason for cancer-associated death. The prognosis of the malignancy is defined by TNM scoring. However, tumor grading, lymphovascular invasion, perineural invasion, and tumor buddings may affect its prognosis. This study aimed to assess the prognostic and histologic impact of tumor budding in colorectal adenocarcinoma.
Methods: This study is a retrospective cohort of 192 patients with colorectal adenocarcinoma. All four stages of colorectal adenocarcinoma patients were included, but the patients in stages I and II were also analyzed separately. We used pathology reports to extract the histopathologic data. The prognostic values were extracted by calling the patients.
Results: Less than half of the patients were in stages I and II of the disease. According to our analysis, tumor extension and lymphovascular invasion were correlated with tumor budding count in patients in stages I and II, and lymphovascular invasion, tumor grade, tumor stage, lymph node involvement, tumor extension, tumor site, metastasis, and five-year survival were correlated with tumor budding within all stages.
Conclusion: It is recommended that tumor budding count should be assessed and reported in pathology reports of adenocarcinomas due to its high correlation with poor prognosis.
背景与目的:结直肠癌是癌症相关死亡的第二大原因。恶性肿瘤的预后由 TNM 评分确定。然而,肿瘤分级、淋巴管侵犯、神经周围侵犯和肿瘤萌芽可能会影响其预后。本研究旨在评估肿瘤出芽对结直肠腺癌预后和组织学的影响:本研究是一项回顾性队列研究,共纳入 192 名结直肠腺癌患者。所有四期结直肠腺癌患者均包括在内,但也对 I 期和 II 期患者进行了单独分析。我们使用病理报告来提取组织病理学数据。我们通过呼叫患者来提取预后值:结果:不到一半的患者处于疾病的 I 期和 II 期。根据我们的分析,Ⅰ期和Ⅱ期患者的肿瘤扩展和淋巴管侵犯与肿瘤出芽数相关,而各期患者的淋巴管侵犯、肿瘤分级、肿瘤分期、淋巴结受累、肿瘤扩展、肿瘤部位、转移和五年生存率与肿瘤出芽数相关:建议在腺癌病理报告中评估和报告肿瘤出芽数,因为它与不良预后高度相关。